Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as anle138b (TEV-56286)
anle138b · 1 trial · 1 indication
PK parameter: Cmax for caffeine.
PK parameter: Cmax for midazolam.
Cmax for caffeine.
Cmax for midazolam
PK parameter: Cmax for caffeine.
PK parameter: Cmax for midazolam.
PK parameter: Cmax for TEV-56286.
PK parameter: Cmax for TEV-56286 (Part II).
| Arm | Type | Description |
|---|---|---|
| anle138b (TEV-56286) as perpetrator (part I) | EXPERIMENTAL | Drug: TEV-56286 300 mg QD (single dose and multiple dose for 14 days) Victim drugs: Caffeine 200 mg Midazolam 2 mg |
| anle138b (TEV-56286) as victim (part II) | EXPERIMENTAL | Drug: fluvoxamine 100 mg QD for 5 days Victim drug: TEV-56286 150 mg QD for 14 days + 5 days of co-administation with fluvoxamine |
| Name | Type | Description |
|---|---|---|
| anle138b (TEV-56286) | DRUG | Anle138b (TEV-56286) as perpetrator |
| Fluvoxamine 100 mg QD for 5 days | DRUG | Anle138b (TEV-56286) as victim |
Inclusion Criteria: * Healthy males or healthy females of non-childbearing potential * Must provide written informed consent for participation in the study and must be able to understand the study requirements * Body mass index (BMI) 18.5 to 32.0 kg/m2. * Must agree to adhere to the contraception r...
anle138b is an investigational small molecule drug being developed by Teva Pharmaceutical Industries Limited under the code TEV-56286. It is in Phase 1 clinical development. The specific diseases or conditions it is intended to treat have not been disclosed.
anle138b is being developed by Teva Pharmaceutical Industries Limited, which trades on the New York Stock Exchange under the ticker TEVA. The company refers to the compound by the internal code TEV-56286.
anle138b is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, and no trials are currently active.
anle138b has been studied in one completed Phase 1 trial, NCT05532358. That drug-drug interaction study assessed the CYP1A2 and CYP3A4 interaction potential of TEV-56286 (anle138b) in 54 healthy volunteers in the United Kingdom. No trials are currently active.
Yes. anle138b and TEV-56286 are two names for the same investigational compound. TEV-56286 is the internal development code used by Teva Pharmaceutical Industries Limited, while anle138b is the compound name. Both refer to the same small molecule drug.
Trial NCT05532358 was a completed Phase 1 drug-drug interaction study of TEV-56286 (anle138b). It assessed the CYP1A2 and CYP3A4 interaction potential of the compound in 54 healthy volunteers in the United Kingdom. The study was controlled and enrolled adults aged 18 years and older.